# AltruBio Inc.

> AltruBio is a clinical-stage San Francisco biotech developing first-in-class immune checkpoint enhancer antibodies for autoimmune and inflammatory diseases. Its lead program, ALTB-268, targets PSGL-1 to restore T-cell homeostasis, and is advancing through mid-stage trials in ulcerative colitis. The company rebranded from AbGenomics in 2020 under CEO Judy Chou and closed an oversubscribed $225M Series B in 2024.

- **Founded:** 2006
- **Headquarters:** San Francisco, United States
- **Founders:** Judy Chou (President & CEO (joined 2020 in rebrand from AbGenomics))
- **Team size:** ~28 employees
- **Products:** ALTB-268, ALTB-168, PSGL-1 / T-Cell Checkpoint Regulator Platform
- **Notable:** Closed up to $225M oversubscribed Series B in May 2024, Total funding ~$327.7M cumulative, ALTB-268 advanced into Phase 2a in biologic-refractory ulcerative colitis

## Products & services

- **ALTB-268** — A potency-enhanced, first-in-class anti-PSGL-1 immune checkpoint enhancer antibody. In Phase 2a for biologic-refractory ulcerative colitis, with a global Phase 2b (ASCEND-UC2b) planned.
- **ALTB-168** — An earlier-generation anti-PSGL-1 antibody with completed Phase 2a results in ulcerative colitis, psoriasis and psoriatic arthritis, and Phase 1 work in steroid-refractory acute graft-versus-host disease.
- **PSGL-1 / T-Cell Checkpoint Regulator Platform** — Antibody platform agonizing the PSGL-1 checkpoint to restore T-cell homeostasis in autoimmune and inflammatory disease.

## Achievements

- Closed up to $225M oversubscribed Series B in May 2024
- Total funding ~$327.7M cumulative
- ALTB-268 advanced into Phase 2a in biologic-refractory ulcerative colitis
- Positive Phase 2a results historically reported for ALTB-168 across multiple autoimmune indications
- Recognized as a BioSpace Best Places to Work

## Latest updates

- **2024-05** — Announced up to $225M oversubscribed Series B led by BVF Partners with RA Capital, Cormorant, Soleus, Blackstone and aMoon.
- **2023-11** — Initiated Phase 2a exploratory biomarker study of ALTB-268 in biologic-refractory ulcerative colitis.
- **2020** — Rebranded from AbGenomics; Judy Chou (formerly of Bayer) joined as President & CEO.

## Links

- Website: https://altrubio.com
- LinkedIn: https://www.linkedin.com/company/altrubio

---

Profile page: https://yespress.io/altrubio-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-29